Reddit Posts
Sintana Energy Update - Operator Galp Makes Second Major Discovery in Namibia's Orange Basin - Additional Drilling and Testing to Follow in Coming Weeks
Sintana Update by President Robert Bose - Two Well Drilling Campaign & Testing to be Completed by February 2023
Sintana Energy Update - Partner Galp Energia Spuds Mopane-1X Well in Namibia's Prolific Offshore Orange Basin
Sintana Energy Update - Hercules Rig Approaching Namibia's Prolific Orange Basin - Drilling to Commence this Week
Sintana Energy - A Small-Cap Stock Prepares to Spud Four Wells in Namibia's Hot Orange Basin
The Impending Cybertruck Disappointment: High Cost, Low Range
Mentions
A couple off the top of my head: LATAM and 'boots on the ground' in Jamaica! FIRE and the origin of MJ napkin math Not sure if you will, but some here may remember HIP island! ;) Oh, and the OGI.WT craziness period
If I could, I'd post a photo of my OGI.WT tattoo here .. lol
There's data for CR1 in the phase 1/2 trial. This trial is doing CR2 not as an indication, but as a test population. Whether or not they get CR1 at approval, or if they have to do a confirmation trial, I don't know. But it will (eventually) be for CR1 as well. More important than that, this drug targets WT1. And potentially it does so more effectively than any other medication. On top of that, the current generation of this drug is a four peptide variation, but GPS plus, is a seven peptide version that's showing even better data in its preclinical.
am i the only one who bought WT calls last year? ever since we crossed into 2026 this stock has only gone up every single day
Positions doing very well today: RMBS SNDK IRWD LLY WT Bought (back in) on the dip today: ASTS RKLB LUNR IBRX
You will never go back. [https://www.amazon.com/Brondell-Elongated-Stainless-Steel-Nightlight-Oscillation/dp/B074MLZR3Y/ref=sr\_1\_8?crid=SHX1I7KNQ1WT&dib=eyJ2IjoiMSJ9.MbtH0DVpFOYE5TeBKnhW5SVxj6iQpDxNgSsizo71GGQWn0ZVYV9nf-JdDZlVY-r34zBXUEhzY9YvVwmzxr4R9F1OBHasqqyzRPnNMM6FUW2U-\_cFr14C3mIgpMLOh2cmUHb3e9kau3CBMmM9CINXYaTzDbrmzvyqCUl6KNDIF1b1vCnEK7aGKiqib\_KdQu0ix2mMaazPR3w5m\_tQOdliXHaSYWaMNh\_SnhRyYSg37xfMDdYnr1XuM\_GmscsEVUBn90LyHQlO2xaUGTbZX2hcA\_Hm6WRcD1w\_4tbLl4pbLkc.KbQJut\_FeYH-22CcEY5J7RncvRrJ9YauhqaxsX4Cr68&dib\_tag=se&keywords=brondell%2Bbidet%2Btoilet%2Bseat&qid=1768614439&sprefix=brond%2Caps%2C387&sr=8-8&th=1](https://www.amazon.com/Brondell-Elongated-Stainless-Steel-Nightlight-Oscillation/dp/B074MLZR3Y/ref=sr_1_8?crid=SHX1I7KNQ1WT&dib=eyJ2IjoiMSJ9.MbtH0DVpFOYE5TeBKnhW5SVxj6iQpDxNgSsizo71GGQWn0ZVYV9nf-JdDZlVY-r34zBXUEhzY9YvVwmzxr4R9F1OBHasqqyzRPnNMM6FUW2U-_cFr14C3mIgpMLOh2cmUHb3e9kau3CBMmM9CINXYaTzDbrmzvyqCUl6KNDIF1b1vCnEK7aGKiqib_KdQu0ix2mMaazPR3w5m_tQOdliXHaSYWaMNh_SnhRyYSg37xfMDdYnr1XuM_GmscsEVUBn90LyHQlO2xaUGTbZX2hcA_Hm6WRcD1w_4tbLl4pbLkc.KbQJut_FeYH-22CcEY5J7RncvRrJ9YauhqaxsX4Cr68&dib_tag=se&keywords=brondell%2Bbidet%2Btoilet%2Bseat&qid=1768614439&sprefix=brond%2Caps%2C387&sr=8-8&th=1)
SLS009 and GPS are complementary by design: SLS009 targets transcriptional survival pathways to debulk and suppress resistant AML clones, while GPS trains the immune system to maintain long-term control by targeting WT1-expressing leukemic stem cells. Together they address both acute disease biology and durable remission, something neither modality can achieve alone. This creates a platform that spans induction, frontline combinations, and maintenance, rather than a single-use asset.
Roast my pre-DA warrant and right portfolio: $AIIA-RI $DYORW $DNMXW $TDWDR $EVAC-WT $APXTW $KCHVR $AXINR $WENNW
Well, it's that time of the month where I buy a bunch of shit because I want it This round: Timekettle WT2 Edge translator earbuds, ZF Transmission filter kit + Redline D4 ATF + BG ATC Plus, Brembo rotors, Akebono ceramic pads Goodbye $1500, the retail dopamine should last through the weekend 😢
The SLS gang didn't prove shit, yet people blindly follow them. Reality is that WT1 vaccines have so far all failed, SLS has a tendency of postponing results of trials and the. sampling they used in previous trials is questionable... it's prone to a lot of errors... You are basically holding stock that is more likely to fail for multiple reasons, than it is not. Having an entry at <1$ is amazing... but right now? hell no.
I got banned from the main subreddit for trying to post bearish sentiment. I'd also like to add that they've been trying to approve a vaccine that targets the WT1 antigen for over 20 years and they all failed. 0 approvals.
Here are my 2 cents. **KFIIR** (rights, 15:1 ratio) - very undervalued. These aren't just finance guys; they are industry titans in experiential entertainment - think casinos, live events, resorts, and mobile gaming. It is a massive industry that many people overlook because it’s not purely digital. It’s complex, involves physical assets, and requires a deep understanding of consumer behavior in the real world. Recently their sponsor invested in a company called Kinectify. Kinectify develops anti-money laundering (AML) and risk management technology for the gaming industry. It shows they are active and knowledgeable in a very specific, high-growth niche that combines technology with regulated industries - exactly the kind of target that could thrive in the public markets. **FTW-WT** (former EQV-WT, trading at pre-DA prices) - massively undervalued. Already signed DA with Presidio Petroleum. Presidio is confirming a $1.35 annual dividend, which is a massive \~13.5% yield at NAV. That yield creates a hard floor for the common stock - it simply can't crash like a typical pre-revenue de-SPAC without the yield becoming absurdly high. If anything, it should re-rate to $13-15 to match the \~8% peer average. Also, the deal looks locked and loaded. They just filed the 3rd S-4 amendment and announced the post-merger Board, which is a huge signal that closing is imminent. With institutional backing from players like Magnetar and Fort Baker, the redemption risk seems much lower than usual. It’s a cash-flowing PDP play, not vaporware. **IPODW** (as you mentioned) - because of AI. **EVACW** \- same sponsor as FTW, but no deal yet. **DNMXW** \- energy, power, digital assets. **APXTW** \- massively undervalued SPAC. Large trust fund, cheap warrants.
OK great, you are seeing the light. Drug will work or not. Now let's see your break down on company valuation. Inputs are: \-total target population \-annual treatment cost (150k - 200k is fair IMO based on what other similar treatments go for) \-market share assumption (no approved drugs in AML CR2, GPS will become standard of care - strong likelihood of being used in CR1 setting; not to mention WT1 is overexpressed in a variety of other cancers. The WT1 protein is the #1 cancer antigen... platform potential beyond just AML treatment. Now factor in SLS009 value. \-modeled peak sales multiplied by a factor (4x - 8x is fair). Run some models and see where you end up. Keep in mind that GPS and SLS009 have the Orphan Drug Designation, Fast Track Designation, and Rare Pediatric Disease Designations, which offer certain benefits, including exclusivity/patent protection. For me, and my analysis, 10B is the floor, and 25B is not an impossibility. If you have never seen a bidding war scenario in the disclosure documents after all is said and done, the bids can go quickly! Ultimately, anyone investing has to dperform their own DD...
You are a moron, I am shocked you were able to spell half the words in that, must have used ai to proof it. First, Keytruda started with ONE indication when it was approved (like almost every drug) and it was for an even more rare type of cancer. It now has 42 indications across 18 types of cancer, that is called expanding the use of a drug through continued trials. Apparently you aren't aware of that process. Second, SLS has two therapies, one that treats WT1 and another that is a CDK9 inhibitor. I will keep it very simple for you as you are a simple audience. These two proteins show up in a combined 35-40 types of cancer. Both of the therapies are blowing away the BAT competition in cancers that other drugs are afraid to even test in, let alone actually have an indication for. Thirdly, these are on pace to be the first two therapies approved as part of the early AI research done in the late 2010's. The first therapy was discovered by Memorial Sloane Kettering, I don't expect you to know who they are but they were recently recognized as the top cancer research center in the World, they are not a joke. Sellas is partnered with the likes of MD Anderson and MSK for their trial sites and several of the lead physicians are recognized as the top researchers for AML. I hope you short the hell out of SLS, post your position, keep going deeper and deeper into a position for a company you have no understanding of. Good luck.
1M WT1+ diagnoses each year. Pure Lying Short Bs from the OP
Nice try but your mixing old, failed cancer vaccines with GPS, which isn’t accurate. Earlier WT1 vaccines used native peptides and were weak. GPS uses modified (heteroclitic) WT1 peptides designed to break immune tolerance and generate real T-cell memory. Just look into it a bit better. Just rewatch the R&D call from past October 29
I wish GPS would be approved already so it can cure this cancer of a "DD" post. Full of half-truths and lies. I don't believe someone is this god awful at "DD" so I have to assume you're a short who got caught with their pants down. There is way, way too much to dismantle so I'll go about one of the half-truth and one of the full lies: true GPS is not Keytruda, \_yet\_, but Keytruda started with 1 indication and now has 40. A drug/treatment needs to start somewhere then is branched out to other areas it can treat. GPS is not targeting one cancer type, GPS can treat ANY cancer with the WT1 protein, including solid tumours as demonstrated by multiple P1 and P2 trials. The FDA recommended CR2 for the P3 GPS trial as the \_fastest route to market\_ AND against a cancer that has 0 treatment options at this phase, not because GPS didn't show efficacy in other cancers. You had 5 years to short this bud. I don't think the right time was after the trial passed 4 futility tests, had its dosing changed twice and finally to ad infinitum, or 21 months after the final enrolment of the last 20 patients for a cancer that has a median OS of 5-8 months (12 month survival maximum as a "rare outlier" described by the top 4 doctors in the field) for a trial that was expected to hit its 80th events over 6 months ago. I have no clue where share price is going in the near term - no one does. But it is clear in the next 4 - 12 months that this stock will be firmly in the double digits and is a clear buyout target from several BPs who are facing a patent cliff. And everyone know this - AbbVie just moths ago terminated three separate trials where they were using their BAT against AML CR1 and CR2 due to futility. Hmm... so BAT has once again, and three times over, shown futility against this cancer type (against healthier cohorts mind you), and we have a trial here where patients are going on their 3rd and 4th years of survival for something with a well documented median OS of 5-8 months. Hmmm... and a phase 2 trial that demonstrated 5.4 median OS for BAT and a 21 median OS for GPS \_before\_ ad infinitum, with a p value of 0.02. HHHHMMMMMMMMMM. Biopharamas are inherently risky, but if you can't see how SLS has been derisked as much as you can possibly dream for, there is no helping you and you should just go to the casino since your performance in the market will be dictated by random forces anyway.
I don’t disagree with some of the points that you’ve made, but I also look at this through a slightly different lens. First, on BAT survival: if the claim is that AML patients in CR2 who are transplant-ineligible now achieve 10–12 months median OS on BAT, and that figure is being used as a base-case assumption in your HR analysis to determine a probability of success for the trial, that really needs a clean, apples-to-apples citation or reference in the maintenance-from-CR2 setting with OS measured from randomization. Absent that, the commonly referenced benchmarks for this population remain in the single-digit month range, and is still widely referenced in the hematology community. Obviously, small sample sizes can produce distortions, but a 10–12 month median OS for BAT would be unprecedented in this setting and, in my view, should be treated as a stressed case from an analysis standpoint, not a base case. Second, on interpreting the event dynamics: I agree they’re not a smoking gun. But calling a sustained post-interim slowdown in events “statistically worthless” overstates the case. It’s directionally positive, particularly given that prior Phase 2 data showed a late-forming survival tail in the experimental arm. I fully agree the study is blinded and that the tail could theoretically be attributed to BAT because we just don’t know yet. My argument is simply that it’s more reasonable to expect Phase 3 to track closer to observed Phase 2 behavior than to assume BAT outcomes that would contradict both historical data and consensus amongst hematology experts for this patient cohort. Finally, on dilution and buyout: if Phase 3 fails, they’ll further dilute to focus on SLS009, no argument there. But if Phase 3 succeeds, history suggests these assets are far more likely to be partnered or acquired than slow-walked through multiple fully diluted trials. Large pharma with global infrastructure prefers to run commercialization end-to-end rather than leave it to a tiny standalone organization. A buyout is made more likely by the 2029 patent cliff, where large pharma needs de-risked assets to protect forward revenue, which is a major tailwind for biotech M&A over the coming years. AbbVie, in particular, would have reason to care if a competitor like Pfizer or Merck for example acquired a validated Phase 3 asset with platform potential in other areas where the WT1 antigen is prevalent, and encroaching on their market share within AML. I’m not claiming this meets its primary endpoint with 100% certainty. I’m saying the bearish case overstates how “settled” BAT improvement is, while understating how quickly the strategic calculus changes if Phase 3 is positive. I personally took a large position in early December when the stock was in the $1.50-$1.60 range after tracking this name for months (1,500 calls with varied expirations ranging from 1/26 - 1/27 with $2.5-$3.0 strikes) I took the insider purchase of 60,000 shares in November to validate my directionally positive thesis on the trial and felt comfortable with the risk given the asymmetric upside at that point in time.
AML Initial Diagnosis BAT is either a fixed duration or continuous therapy. If complete remission is achieved, patients usually survive for 18-24 months with gruelling side effects of the currently best available drugs. Should the AML relapse and CR2 be achieved, the life expectancy is grimly months, not years. GPS has proven to boost overall median survival to >60 months in first line, which was 18-24 months previously with current standard of care. 21 months in second line with GPS, comparatively less than a year with current standard of care. It’s important to note that the median overall survival (mOS) is estimated to be 6-8 months in patients who do not receive transplant in CR2. Transplant is NOT allowed in REGAL patients after CR2 and before enrollment. Transplant is the only potentially curative treatment for most AML patients, but only about 40% of AML patients can receive a transplant; approximately half of transplanted patients are cured but, even then, the patient can experience a relapse. Should a relapse happen on HMA+ventoclax combination, (the current standard of care), the survival is only about 2.5 months. Survival remains limited in patients who achieve response. GPS maintenance HAS PROVEN in earlier trials to significantly prolong survival. >60 months in first line patients in remission. 21 months in second line patients in remission. The longer the duration of REGAL phase 3, the more likely it is that the numbers will match previously done trials, if not blow them out of the water with even better results. Multiple cancers express WT1, but in AML it is more than a 95% expression. It is an over expression. GPS is an off the shelf drug, not patient specific. It is easy to administer, with no known harmful side effects aside from local reactions. It is a subcutaneous vaccine that can, with collected trial data, be administered ad infinitum with, let me repeat, safe to date the only known side effect to be a local reaction (subcutaneous injections might cause irritation around the skin where the injection administered). Look, I could write even more, and to anyone who has read this post; I urge you to, if you haven’t yet, research into SLS. All of the above information is from last October’s virtual R&D Day. It is 2 hours long, with great slides filled with data. And doctors with actual clinical experience. GPS could be the first in class & best in class AML treatment. I think every single point of OP’s can be broken down and explained scientifically with data to back it up. It’s just a huge wall of text, pointless garbling. Even if it were to be true and GPS somehow fails; would you not want to dream big? What GPS could potentially achieve is nothing short of groundbreaking. Think of the physicians who have to break the news to their patients, that their life expectancy is months should they receive the standard of care treatment. With GPS, it could be years. It could be a monumental vaccine.
Really? I thought the first patient started 45 months ago? Anyway, YOU should be able to answer my really basic questions here: Why did both MRK and BMY run away, instead of continuing their collaboration trials into Phase 3? Why did 3D Med decide that GPS wasn't worth paying the milestone to get? WT1 was always a great target in theory. But there are no approved peptide oncology vaccines, in spite of numerous attempts (e.g. Sellas' old asset NPS, that Stergiou used to say that he was on the verge of selling "to an Asian company" but now has become the "let us never speak of that again" subject in SLS). We can't just use "historical controls" to tell whether GPS is working, because trial patients are screened for comorbidities. Why didn't the three companies that had inside information on GPS get interesting in continuing collaboration with Sellas? And why did Stergiou say that he "didn't want to have all his eggs in the GPS basket" back when he bought SLS009? I'd like to have a bigger position here... but whenever I ask these basic questions, I just get obscenities and death threats instead of answer. TIA to anyone who can clear this up, I imagine that someone here can.
I hope now that we have more people looking at Sellas, someone that has done more DD (and that isn't from Lidingo) will be able to answer the obvious questions here. Why did both MRK and BMY run away, instead of continuing their collaboration trials into Phase 3? Why did 3D Med decide that GPS wasn't worth paying the milestone to get? WT1 was always a great target in theory. But there are no approved peptide oncology vaccines, in spite of numerous attempts (e.g. Sellas' old asset NPS, that Stergiou used to say that he was on the verge of selling "to an Asian company" but now has become the "let us never speak of that again" subject in SLS). We can't just use "historical controls" to tell whether GPS is working, because trial patients are screened for comorbidities. Why didn't the three companies that had inside information on GPS get interesting in continuing collaboration with Sellas? And why did Stergiou say that he "didn't want to have all his eggs in the GPS basket" back when he bought SLS009? I'd like to have a bigger position here... but whenever I ask these basic questions, I just get obscenities and death threats instead of answer. TIA to anyone who can clear this up, I imagine that someone here can.
I hope someone that has done more DD (and that isn't from Lidingo) will be able to answer the obvious questions here. Why did both MRK and BMY run away, instead of continuing their collaboration trials into Phase 3? Why did 3D Med decide that GPS wasn't worth paying the milestone to get? WT1 was always a great target in theory. But there are no approved peptide oncology vaccines, in spite of numerous attempts (e.g. Sellas' old asset NPS, that Stergiou used to say that he was on the verge of selling "to an Asian company" but now has become the "let us never speak of that again" subject in SLS). We can't just use "historical controls" to tell whether GPS is working, because trial patients are screened for comorbidities. Why didn't the three companies that had inside information on GPS get interesting in continuing collaboration with Sellas? And why did Stergiou say that he "didn't want to have all his eggs in the GPS basket" back when he bought SLS009? I'd like to have a bigger position here... but whenever I ask these basic questions, I just get obscenities and death threats instead of answer. TIA to anyone who can clear this up, I imagine that someone here can.
I hope now that we have more people looking at Sellas, someone that has done more DD (and that isn't from Lidingo) will be able to answer the obvious questions here. Why did both MRK and BMY run away, instead of continuing their collaboration trials into Phase 3? Why did 3D Med decide that GPS wasn't worth paying the milestone to get? WT1 was always a great target in theory. But there are no approved peptide oncology vaccines, in spite of numerous attempts (e.g. Sellas' old asset NPS, that Stergiou used to say that he was on the verge of selling "to an Asian company" but now has become the "let us never speak of that again" subject in SLS). We can't just use "historical controls" to tell whether GPS is working, because trial patients are screened for comorbidities. Why didn't the three companies that had inside information on GPS get interesting in continuing collaboration with Sellas? And why did Stergiou say that he "didn't want to have all his eggs in the GPS basket" back when he bought SLS009? I'd like to have a bigger position here... but whenever I ask these basic questions, I just get obscenities and death threats instead of answer. TIA to anyone who can clear this up, I imagine that someone here can.
Therapeutic cancer vaccines haven't worked, but more specifically a WT-1 peptide therapeutic cancer vaccine has already failed vs pbo (a weaker control than BAT!) They've run about 10 trials, only one of which was an RCT. It showed a very mild OS benefit and was not powered for statistical comparison. Also in the AML/MDS study, the vaccine is also called into question, as it doesn't even seem to consistently induce T-cell responses. Never mind whether or not inducing them would prolong survival, given that it did not for OCV-501
Therapeutic cancer vaccines haven't worked, but more specifically a WT-1 peptide therapeutic cancer vaccine has already failed vs pbo (a weaker control than BAT!) They've run about 10 trials, only one of which was an RCT. It showed a very mild OS benefit and was not powered for statistical comparison. Also in the AML/MDS study, the vaccine is also called into question, as it doesn't even seem to consistently induce T-cell responses. Never mind whether or not inducing them would prolong survival, given that it did not for OCV-501
Therapeutic cancer vaccines haven't worked, but more specifically a WT-1 peptide therapeutic cancer vaccine has already failed vs pbo (a weaker control than BAT!)
Their "secondary" drug SLS009 is worth $10.5bn to Abbvie alone as it beat Ventoclcax like a red headed step child in a Phase 3 trials. Ventoclcax makes $abbv over $3bn in revenue. 3.5x P/S. GPS could have peak sales on par with Keytruda of $20+ bn plus if it expands into other WT1 cancers. Even in AML alone it's worth $5-6bn of sales by 2028 for all CR1 and CR2 patients. That makes a buyout of $25bn for the duo likely. But I'll take anything above $16bn
The overexplanation of Vyvanse was my first red flag. Lil bro trying to look smarter by copy and pasting how prodrugs are metabolised to make it look like he knows what's he's talking about to the reader (you don't). Second red flag: WT1 is over expressed in majority of AML and in a lot of other cancers, not just blood cancers like you said. I stopped reading to not waste my time and looking from the replies, I made the right choice. You obviously don't know what you are talking about. Nice AI slop to pad it out tho. Keep buying puts, I want you to fail.
Its painfully obvious you have a severe lack of understanding on how drug trial works and whatever drug you took certainly doesn't help. Just spend 10 seconds googling how a drug trial works and it will tell you that BAT will be limited, in this case BAT actually gets something unlike a sugar dose of placedo but that does not include the V+A combo like I said which is literally stated in the government files... The patients and doctors are bound to a legal contract knowing they can not receive anything other than whats stated or else they are out of the trial. Secondly, the relatively small sampling size sure isn't the big data stats analysis on world reports, but a computer is actually out there to record their key risk factors (age, duration of first remission, cytogenetics) before assigns them to a group to ensure those specific risks are balanced. Its definitely not perfect but this stratified randomization in a group of ~140 patients makes it statistically highly unlikely to have a massive skew that ruins the data based on "luck" alone. Google "stratified randomization in drug trials" will save the both of us time. On my third point, you are literally backtracking. If you admit WT1 is present in 90% of AML patients, then your original math claiming the drug only targets a tiny '1%' fraction is wrong. We aren't pricing this as a cure for everything (like Keytruda), we are pricing it as a standard of care for AML. That alone justifies a valuation higher than the current market cap. Also, REGAL is mainly based on US and EU and I believe the China patients are excluded from the trial since March 2024, so up your research game lmao.
You didn't read my post and it's painfully obvious. \- Never said WT1 is rare in AML, it's rare among other cancers. \- Never said GPS has failed to beat BAT, read the text again. Slowly, you'll find out that I'm talking about the fact that the study isn't necessarily prolonged because of GPS outliving BAT, it can be the other way around or without nay change. \- Your commentary about the sampling methods are laughable, anyone who studied statistics know that this doesn't guarantee a perfect split, especially at such low sampling size (<1000) \- Your other comments are even more laughable, **are you seriously suggesting that when a human being is promised either experimental treatment or the best treatment possible**... he will **not** receive the actual best treatment? How fucked in your head are you? **REGAL isn't China only, it's EU/US as well and in these countries ethics exist.**
no problem! just exciting to talk about it, and the (partial) data released so far looks exciting. Not to mention, minimal side effects, and the target of GPS is WT-1 and it's expressed on a dozen or more different types of solid cancers. The implications for its use beyond AML would be beyond our wildest dreams, provided that it works! Just exciting times.
Tin foil hat level of conspiracy posting so I will put a few simple points to counter your unfounded claims: (I have a massive long position on this so of course I'm inclined to be positive) 1. WT1 is rare: Absolutely not, it is over expressed in more than 90% of AML patients, basically a nearly universal marker for that cancer. This means your reduced revenue math based on the tiny "1%" slice is flat wrong. 2. Keytruda comparison: GPS is a cancer vaccine while Keytruda is a checkpoint inhibitor, so while it's not exactly the same but if GPS works it will be the standard of care in a market without many options, so even a modest $500M revenue would justify a significantly higher valuation than what it's at now. 3. Death statistics: IDMC response suggests otherwise from your "drug isn't working" claim. IDMC has reviewed the unblinded data regularly and repeatedly recommended the trial to continue without modification, so if GPS had failed to beat the BAT arm significantly or there's not enough of a split between the two, the trial would've stopped for futility long ago, no matter how much better BAT has gotten. 4. Survivor bias: Phase 3 trials are randomized and in this case, "Healthier groups" and the "Less healthy" ones are distributed equally between the 2 arms by a computer, so the statistical power is supposed to file out the random chance that you described. I agree on not being overly positive on the drug trial like all biotech bets, like your points on possible dilution and study delays being possibly positive or negative. But please educate yourself and find out the facts and factors behind the trial before snorting more Elon bs ✌️
TAM calcs put company at around 10bil with the typical bio BO multiples. But really the TAM ceiling when taking all WT1 cancers into account + sls009 and we're in 10s of billions BO potential
I know how bad leukemiantreatment is with all the side effects and still lot of people die. GPS and SLS009 are changing that totally. Leukemia will be cured basically with no side effects. Works also 20 other cancers that has WT1 over expressed. Just need money of big pharma to spread. This is a future cancer treatment platform. Bidding war may have already started behind the scenes by big pharma.
Thanks for the kind words! Just connecting dots with the PPD partnership and Thermo-Fisher providing the diagnostic tools for the Myelomatch framework. They carry a wide range of WT1 antibodies for immunohistochemistry as well as WT1 RNA sequencing panels, they also routinely sequence for ASXL1 mutation as part of their Myelomatch routine panel.
bought more RECO.WT just before it doubled!
There are also warrants available. You can buy RECO.WT anywhere with international trading. If your looking for the warrants associated with the past two capital raises (RECO.WTA and RECO.WTB), I think you need to have a Canadian account for those. As a US investor, I tried to purchase those warrants but was denied by Fidelity.
I think 10b is a *fair* floor for the majestic efficacy we see in the data for such a common and at the same time hard-to-hit target as WT1 in AML. With no side effects and basically zero manufacturing costs. 85+% ORR. Massive off-label potential. Perfect combo with the SLS009 CDK9 inhibitor. Tested against myelodysplastic syndrome, MPM, MM, ovarian cancer... Each of these trials is worth billion on average. For some, this will be the first in class and the best in class at the same time.
We may have already discussed this, but the L444P looks to be about 20-25% of the WT control, and GT-02287 increases it by about 360%, which should be very close to the healthy WT level. Pretty impressive. Is there an precedent that you know of that has achieved such a restoration?
*> Also retired, age 66, and not yet taking SoSec\] Not quite sure how you'd get $72k tax free, but that's not important.* [https://www.hrblock.com/tax-center/irs/tax-law-and-policy/one-big-beautiful-bill-senior-tax-deduction/?srsltid=AfmBOorz5WT6Va1kF83z0H1ZGHlgRxp1JDYzwHGACVvHbVD1Pra7e2c6](https://www.hrblock.com/tax-center/irs/tax-law-and-policy/one-big-beautiful-bill-senior-tax-deduction/?srsltid=AfmBOorz5WT6Va1kF83z0H1ZGHlgRxp1JDYzwHGACVvHbVD1Pra7e2c6) *Standard Deduction* Filing Status | Base Std Ded | Add Std Ded 65+ | New Ded For Seniors Single | $15,750 | $2,000 | $6,000 Total= **$23****,750** \---------------------------------------------------------- [https://www.hrblock.com/tax-center/income/investments/how-to-figure-capital-gains-tax/?srsltid=AfmBOoo7m9Vub-vjZDl5KEIfCwJMCLCVG3qZfcsTzY1K5Q5cX6DG9Uhb](https://www.hrblock.com/tax-center/income/investments/how-to-figure-capital-gains-tax/?srsltid=AfmBOoo7m9Vub-vjZDl5KEIfCwJMCLCVG3qZfcsTzY1K5Q5cX6DG9Uhb) [https://www.hrblock.com/tax-center/income/investments/dividend-taxes/?srsltid=AfmBOopgFE8i-DLnfFG0V3WXStqT7moy\_PhrgvfWCqD4rqqQWxAZyUd8](https://www.hrblock.com/tax-center/income/investments/dividend-taxes/?srsltid=AfmBOopgFE8i-DLnfFG0V3WXStqT7moy_PhrgvfWCqD4rqqQWxAZyUd8) *LT Capital Gains and Qualified Dividends Tax Rates* Filing Status | 0% Tax Rate | 15% Tax Rate | 20% Tax Rate Single | Up to **$48,350** | Up to $533,400 |Over $533,401 \--------------------------------------------------------------------- $23750 + $48,250 = **$72,100**. So I can have up to $72,100 of LT Cap Gains and pay $0 taxes. And like I said, I have some taxable interest (which is way less than $23,750 leaving quite a bit for Qualified Divs and LT Gains) and like around $30,000 of Qualified dividends (which counts at LT Gains rate) so it leaves around $3x,000 of LT Cap gains I typically remove each year.
FN TSLA how can the stock be going through roof when it misses earnings and pays the retard with a speech impediment a billion WT flying F
People like you miss the point completely but still act like you are smarter than others. The point was about how people should work on relationships but you seem like a Basic Bro who needs things told explicitly otherwise you would go WT weird stuff.
# GLD * The first US traded gold ETF and the first US-listed ETF backed by a **physical asset** [State Street - GLD](https://www.ssga.com/us/en/intermediary/etfs/spdr-gold-shares-gld?WT.mc_id=ps_etf-wgc_gold-funds_us_google_slink_psb_mf2_sl1-gld_may25&gclsrc=aw.ds&gad_source=1&gad_campaignid=21064617551&gbraid=0AAAAACz5AuOSZNHXeU2roR9-N3mpDBQYw&gclid=Cj0KCQjwsPzHBhDCARIsALlWNG1TWfWQZ8tQbLznjO4E1VEmtpmNan-ahfiW3dPjvN3Q3axfc4o-kQcaAhYgEALw_wcB)
WT literal F? Who invests everything in lentils!!! 🤦🏻♂️
I’ve just had a brief look! Sorry I dont think i’d really consider myself qualified to comment on trials per se, i’ve had no experience there myself, and any conclusions i can draw from it, i.e median survival, effectiveness etc, will be very superficial at best! Their choices of targets (CDK9/WT1) are certainly very valid and I think are pretty well-substantiated! I really like the idea of targeting oncofetal proteins such as WT1 to reduce off-target effects, but at the same time, I wonder if the re-expression of fetal proteins in cancers is actually functionally important to the cancer, or if its just a by-product of aberrant signalling and mutations in cancer. In which case, I dont know if targeting these pathways are always useful, it just applies some kind of darwinian pressure on the tumor to stop expressing it, at no cost to the tumor itself. Im no expert with WT1, but im abit more familiar with AFP, also a oncofetal protein expressed in liver cancer, and I think the same issue kinda arises there, where it seems attractive as a target, but doesn’t seem to have any functional use for the tumor, so you see patients presenting with a whole range of different AFP levels (some even with none). I dont necessarily see anything interesting in the way they are going about it (but that could very easily be from lack of research) so im not sure it’s very novel, or if they have any advantages over other companies also working on these targets. Just a quick look at the clinical trials web, there’s 210 studies when I search for WT-1. Again, not financial advice. Just for the other guy, beep boop beep boop bzzz brrtt 🤖
Meanwhile the stock price is becoming smaller, almost single digit- WT% is going on? They seem to have lost the arbitration with BP- but saying it will not have any material effect, really? I am bidding 8 in case someone panics , then 6, then 4..Kets see how low this POS can sink
[You made your money the old fashioned way.](https://www.youtube.com/shorts/gCsYAQy0WT0)
Haymaker Acquisition Corp. 4 WT (HYAC-WT) warrant $0.63 - up 59% today with higher volume
EVAC-WT, I currently have 25k bought @$0.27/each, plan to hold them through the merger and later. This is their second SPAC. First one is EQV Ventures I already merging with presidio petroleum (warrants trading for $0.5/each). Interesting fact, that [they promise 13,5% yearly dividend yield](https://s204.q4cdn.com/667065784/files/doc_presentations/Presidio-Production-Company-Investor-Presentation-August-2025.pdf) if they go public.
No secret at all. CGCT-WT, PLMK-WT I expect them to jump very soon. Loaded up a bunch of warrants.
WT has been very good for me too, there is a new one Amundi Stoxx Europe defense that looks good but is only 3 months old.
up over half a point on premarket alone, AGAIN. WT FFFFFF
Thanks for the reply. It's an old employer's 401k and the options are limited, I think I might ultimately convert it into an IRA. The options I have for large cap stock include OIEJX, VFTNX, Vang Inst TOTL SK TR, and WT CIF II Growth 2.
Trash and worst team ever. When they just started, giggw was somewhere in $0.04-0.05 price range. Good speculation opportunity. But now? Honestly, I'd not pay 20 cents for this trashy SPAC. Instead, on your place I'd buy EVAC-WT, it's a hidden gem trading with deep discounts (but not for long)
Is that meme head Vance on the left? WT actual F is this guy on 🤦🏻♂️
Thanks for the quick and quite thorough reply. This is what I was hoping for. I feel like a golfer in the PGA who regularly gets around 25th place. Sure, it's a good living, but I would like to know what the guys in the top 10 are doing that I am not. I tried Ross from WT, but getting up before dawn and hoping to pick off a trade before it heads south was both exhausting and not particularly fruitful for me. Plus, it wasn't cheap. I have tried a ton of trading sites: Gorilla Trades, Dave Landry, Real Money, RevShark and a few others I can't even remember but 1) when they post their results, it's generally not that great over the long term or 2) their methods seem to have some special sauce I never get quite right. It may simply be that I am just not good enough to do better than 30-ish percent year over year, but it doesn't hurt to try. OR, maybe that rate is actually pretty good in comparison with some of the better traders, and I shouldn't mess with success (like Tiger Woods did). As to the past year, I have really been pressing to get my rate up. It has worked, but I attribute it more to beginner's luck than actual skill. No way I can keep this up year over year.
Here's an image of the beautiful city of Tehran[Tehran](https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcT3CY_FxU-GWh56JdOVIV0gBAMOP2i9BL-moh7WT9I-vQ&s=10).
CRCL.... 2400+ P/E. WT ever-loving F?!
I managed a chemical program for WT offshore and that is the absolute shittiest company run by idiots.
Withholding tax only. In an IRA you won't pay any if you own the stock directly but the IRA only eliminates only level of WT. That means if you buy a US listed ETF that owns the Canadian stocks directly there is no tax. If you buy an ETF that owns a Canadian ETF for example that you WT applies.
Several Major RED FLAGS with this company (SLS) Source: I attended medical school in the midwest. 1. CEO has concerning credentials. He does not list the school from which he got his MD, and lists it just as "US medicine." 2. The company's approval from FDA is for "Orphan Drug designations" which is for drugs/treatments that affect less than 200,000 people in the US, and is arguably much easier to obtain than other FDA approvals. It gives tax free clinical trials and a few other benefits, but is entirely distinct from the drug approval, which is the real approval that matters. 3. WT-1 gene is known as a tumor suppressor gene although in certain circumstances it can be oncogenic. In laymen terms, this means WT-1 suppresses or fights cancer but can sometimes make cancer worse in certain situations. Targeting this gene may not help you get rid of cancer for the aforementioned reasons.
Why SLS (Sellas lifesciences) SLS has 2 first in class and best class assets. Most immediately, their phase 3 asset, is GPS. It will mark any WT-1 ( wilms tumor 1) antigen for destruction by the immune system. Training t cells. WT1 is prevalent in many cancers, but cancer trials are expensive. Sellas decided to study AML (leukemia) patients that are not eligible for bone marrow transplant and are CR2–CR stands for Complete Remission. The 2 means for the 2nd time. The CR2 population generally has a mOS (median Overall Survival) of 6-8 months. Many many studies have proven this out, with a slightly higher mOS in some studies. Overall Survival (OS) of 13 months is not common—in the single digits percentage wise. Although the Regal trial—this phase 3 trial is only looking at CR2 AML patients, many think that GPS will be used earlier in the. disease progression as well as many other cancers that exhibit the WT1 mutation. To be clear, GPS will be used as a maintenance phase in remission. Sellas chose this group because there are no other viable answers. Data. This study started with 128 people. People enrolled as they qualified. Beginning enrollment started in 2021 and ended in early 2024. Right now, the last enrollee was admitted is 15 months. From an unrelated study, but with GPS data overlayed, you can see something. Back in Dec 2024, we learned than 60 events (deaths) had occured. Know knowing that KOL(key opinion leaders) have already stated that that 12 months OS is rare, and that 6-8 months is the norm. This is BAT (best available treatment) aka the control. There is nothing to suggest that GPs is not absolutely saving lives. In phase 2, they did not screen for wt1 mutations—and the immune response was only 68 percent. But in phase 3, all where screened and we got 80 percent ORR (overall response rate). In phase 2 the mOS was 21 months. This response rate is referring to the immune response. Definition—mean is half not average. So in phase 2, it took 21 months before half of the people had an event. Many lived longer. Their ORR was only 68 percent bc they didn’t funnel the intake criteria to WT1 positive. Phase 3 did. At IA(interim analysis), the IDMC ( Independent Data Monitoring Committee) said that there is no futility, toxicity or changes to the study necessary. This was announced in jan 2025. The 60th event happened in dec 2024. So it has been several months with bo announcement. The gamble!!! The only gamble is that someone thinks thats these extremely sick patients who have had zero answers, have miraculously recovered! The real answer—i am qualified to answer—is market manipulation, naked short selling and OTC trades with options hedging. That is part of it, the other is warrant conversions. But regardless of what the market makers do to suppress the stock price, none of it will matter when phase 3 data is released. They have a fast track designation for FDA approval and have what is called a rolling BLA —essentially, they have already started the FDA approval process, just waiting on final data. Input all of this into chatgpt or someother AI and see the truth. If you see falsehood!!! Let me know!!!! Anyway, that is the first asset, but not even the best. GPS is amazing, but it is for those in remission. The asset in phase 2 is a debulker. It is for active cancer. A CD kinase! Oncology has been searching for rhis. Other kinases have worked but have been toxic —bc they were not specific enough and stuck around too long. This sls009 is only in phase 2. There are 5 cohorts in this study. The first 3 cohorts top line data has been released and have shown 2-4x mOS increase over standard treatment. Sls009 data due any day now. GPS data due any day now. SLS just got the green light in to the russel 2000 index—forcing more institutional buys. 13gs showing more buys in the last 6 weeks from institutions—recently3 form4s Getting spicy!!! 6-17-2025 Update! And other important points not previously discussed. Today there was the annual meeting for SLS which was virtual. Maybe the recording will be available tomorrow, if so, I will post the link here. Take aways—there are some GPS patients living past 3 years and many living past 2 years. Looks like phase 3 will surpass phase 2 numbers. The trial protocol, which is tightly controlled by the IRB and the FDA, was modified for GPS from the last dose at 13 months to ad infinitum or relapse. Remember rare for control group to get to 12 months, and half expire 6-8 months. The mOS for phase 2 was 21 months. Data readout or topline for phase 2 sls009 was due 1st half of 2025—readout delayed to 2nd half. Why? Patients are living longer than expected. A big deal, about a month ago, a 12 year old was admitted to the phase 2 trial. Hard to imagine that anyone with knowledge would allow a pediatric patient be admitted to a drug trial that had poor outcomes. Other developments—new protocols at the FDA to streamline approvals, especially for indications that have no solid treatments. Possibly opening the door for FDA approval of phase 2 drugs like sls009. Back to the call—the CEO stated that sls009 will become a platform drug. Not just for one indications, but across multiple indications—think keytruda! Other considerations—there is a steep patent cliff and many big pharmaceutical companies are looking for replacements. GPS will probably end up being approved for other indications. This is the pipeline currently. Link didn’t directly post… but this. https://sellaslifesciences.com/pipeline/#indications
Check Form 4 for confirmation of selling. Many insiders filed for intent to sell today (Form 144). Only thing I can confirm is CEO recently sold 9,280 shares on June 9, 2025. Here’s the link to the relevant filing: https://www.sec.gov/Archives/edgar/data/1824920/000195004725004170/xsl144X01/primary_doc.xml Stock is running hot and P/E is crazy. BUT avoid going all in on short selling with money you can’t afford to lose. maybe a good long put play. Here’s a link to all the filings of IonQ: https://www.sec.gov/edgar/search/#/ciks=0001824920&entityName=IonQ%252C%2520Inc.%2520(IONQ%252C%2520IONQ-WT)%2520(CIK%25200001824920)
I bought QBTS-WT last year in 2024 while trading around .12. Bought $700 worth. Ended up with about 6800 warrants. I sold for a 10% loss & in August. Worst sell of my life thus far. I also bought $700 QUBT and $700 RGTI common. The QBTS warrants are trading at $15 today. I worry this will be the stock I tell my grandkids I bought and they won't believe me LMAO. So painful.
Sellas Lifesciences $SLS The have a WT-1 vaccine in phase 3 and a CDK-9 inhibitor in Phase 2a. Both drugs look very safe and effective, they are currently being developed for AML but will propably be useful for a variety of cancers.
Taxes!? And Wealth?! Are you kidding me? When no tax on tips, overtime, and SS was voted nay by every single democrat. If this is about rich people getting cheaper cars to stay rich tax break then WT total F are the dems about when they frankly screw middle and lower classes by literally voting against money in the pockets of every day working Americans?
[Official inflation](https://www.reddit.com/r/economy/s/GFR3Sed3WT) remains a lie. Unemployment has been a lie since the dotcom bubble: [LFPR is wobbling](https://fred.stlouisfed.org/series/CIVPART), which accurately reflects the reality that nobody knows what to expect next. Fewer shipping containers is merely predictive: when it translates to less actual spending it will become an actual problem.
Who makes a deal with a deal breaker? WT ACTUAL F.
Shill alert. Wildly optimistic market expectations. The "realistic" market value (PV of realized cash flows) of GPS is highly uncertain and modest when properly risk-adjusted. While the theoretical market potential across multiple WT1-expressing cancers is large, the path to realizing that potential is fraught with clinical, regulatory, and commercial hurdles, particularly strong competition from cheaper competing therapies which do not provide a cure. A realistic assessment acknowledges that while transformative success w GPS is possible, the probability-weighted outcome incorporates a high chance of failure or only niche market adoption, significantly limiting probabilistic cash flows.
I'm using EUAD, I'll check to see what the ticker is for the WT one.
\*phew\* I was getting worried about my puts, but this is a good top signal: [https://www.tradingview.com/news/reuters.com,2025:newsml\_L1N3QS0WT:0-s-p-500-s-death-cross-may-not-be-as-ominous-as-it-sounds-analysts-say/](https://www.tradingview.com/news/reuters.com,2025:newsml_L1N3QS0WT:0-s-p-500-s-death-cross-may-not-be-as-ominous-as-it-sounds-analysts-say/) 
Whole Crap! Long end BONDS continue to CRASH. WT is happening to the American Economy??
It's insane actually. NVDA should be 90% separate from OXY except that maybe you could claim energy costs increasing my eat into shipment costs for NVDA's chips, but a direct 100% correlcation? Nah, like WT actual F?
PBOC has set the reference rate at 7.0238 to balance the effect of tariffs https://blinks.bloomberg.com/news/stories/SUEN8WT0AFB4
Yoooooo WT - just coming out of my office meeting and my poots are fk 😱
If course he wasn't bad, he was great. Trump ran under white entitlement and WT make him their personality.
i still use WT-NMP on windows, AMA
what indicators tell you this? Everything I got - everything that was tried and true 3 months ago - can't follow this market. RSI, MACD, DMH, WT Osc, LuxAlgo Smart Money. All of them, failing. So, what you got?
I think you're uneducated and WT
stocks aren’t looking to hot anybody have recommendations for bourbon instead? I like: woodford double oaked, OF 1910, WT101
Someone made a map of what could be its path entering the atmosphere. Idk how accurate that would be. [potential path ](https://www.google.com/search?client=ms-android-att-us-rvc3&sca_esv=7833c6f0638101e1&sxsrf=AHTn8zqikkqaFhJFY_yShrE79K_7WT7Uuw:1740013833696&q=asteroid+2024+yr4+path&udm=2&fbs=ABzOT_DnPN66xNYYiVBYF80MNa9-5BDfTz-lcNf-EHVAQdgjXVe8YVZiOUJw4pag-c97NBCLlCrYEQqooQJjBzweXf-UNyNJQXKWijYybEUgDv0dGQq3BioQP0NjwW2g7dhhZM-Bkch2ZmQPyZUWgAn4GKnX8X1x9RTkFmUHfpH4ingy1FLVyL0v43u_ZPjsS3M4iNhUBqMM0MSAlYwKzljjnX1a5GPYJzbmF2Z81JCm90Ilz3CKlJI&sa=X&ved=2ahUKEwjFvNjTiNGLAxVZM1kFHWZGNeoQtKgLegQIDBAB&biw=412&bih=750&dpr=2.63#vhid=oVNL0R1ncX6HmM&vssid=mosaic)
Listen to Palmer Luckey on Shawn Ryan today. Really interesting about the future of warfare. https://youtu.be/bwSycrvcwAs?si=F4WT0VZf_ZJpw8nn
[https://imgur.com/WT3FDSD](https://imgur.com/WT3FDSD)
Congrats! I'm new to Warrants and haven't read much. But your success made me start looking into warrants and have learnt that most of that have an exercise price of $11.50. I started looking at warrants of stocks that are doing well in the last 90 days. I came across [BKSY.WS](http://BKSY.WS) BlackSky Technology Inc. WT EXP 090926. While it's underlying stock BKSY is already trading at $16.50, I'm not able to understand why the warrant price is trading only at $0.31 (31 cents) and does not reflect the gain someone could make if they had to exercise the warrant as the exercise price is cheaper than the stock price.
Huh yeah, looks pretty interesting. . . . https://www.youtube.com/watch?v=WT0zESO_GJ4
>First, I’m not in the market for a EV truck, but I do believe that both the CyberTruck and Silverado EV cost north of $100k in any useful configuration. That is not a large market. When MKBHD did his excellent review of the Silverado he showed a funny post from Zillow of it listed there with a mortgage estimate. I think the one he reviewed was $120k. Great truck. Okay, no. Let me correct you again. The Silverado EV tops out at about $97K. And that's for the fully loaded RST (the highest trim). The WT (Work Truck) is the lowest trim. That's the model they tested against the CyberTruck in the video I linked. That read the "cheap" model. It goes for around $57K. Less if you get the tax credits. So you're proving my point here. The CyberTruck costs significantly more than the Silverado EV, and even the lowest level trim Silverado EV completely blows it away, for around half the price. >Almost all EVs that are sold are sedans/SUVs. EV trucks is currently a niche with maybe 1-2%. Why do you concentrate on that market in this thread? Because that's Tesla's newest product. You're here claiming they're the best across the board and nobody can surpass them. Well reality check for you. Pickups have been the best selling vehicles in the US for like 50 straight years. The Ford F series has been the #1 selling vehicle for 47 straight years. The Silverado is right behind it. EVs are mostly sedans and SUVs because Tesla was the only EV manufacturer and they didn't sell anything else. Now the other manufacturers are selling what the public has always preferred (trucks) as EVs. Tesla is attempting to join them, but, as you yourself already stated, the CyberTruck is trash and costs north of $100K. This cannot be ignored if we're talking about the long term market leader.
Let’s go QBTS + QBTS-WT!!
Sao Paulo already has the largest private helicopter fleet in the world. It's either that or risk getting kidnapped by gangs for the ultra-rich. With 260 helipads, they never have to set foot on the dirty ground like us poors. As more countries become oligarchic third world dystopias, I can see helicopter/eVTOL transportation becoming the norm. I work in the WT Center and I see a fair amount of helicopter traffic around NYC.
Everest Consolidator Acquisition Corp \['MNTN', 'MNTN-UN', 'MNTN-WT'\] trust account is possibly bankrupt. After 99% of shares were redeemed and reported on 11-29-2024, the trust value currently sits at $322,386.00 with 27,927 outstanding Class A redeemable shares. The SPAC is behind on its current 10-Q for quarter ending 9-30-2024. The last 10-Q was for quarter ending 6-30-2024. The SPAC reported $2,505,856 in income tax payable. Income taxes and franchise taxes can be withdrawn from trust. Unless the SPAC withdrew the income tax payable in the last quarter, the SPAC's has a much higher income tax payable then the cash held in the trust account. 2nd Quarter 10-Q: [https://www.sec.gov/Archives/edgar/data/1863719/000141057824001518/mntn-20240630x10q.htm](https://www.sec.gov/Archives/edgar/data/1863719/000141057824001518/mntn-20240630x10q.htm) 8-K from last redemption vote: [https://www.sec.gov/Archives/edgar/data/1863719/000182912624007895/everestconso\_8k.htm](https://www.sec.gov/Archives/edgar/data/1863719/000182912624007895/everestconso_8k.htm) Per trust agreement, if the taxes are more than the cash held in trust, the SPAC cannot pay less than $10.00 per share (the IPO trust amount): >"(j) Upon written request from the Company, which may be given from time to time in a form substantially similar to that attached hereto as Exhibit C, withdraw from the Trust Account and distribute to the Company the amount of interest earned on the Property requested by the Company to cover (i) expenses relating to the administration of the Trust Account and (ii) any income or franchise tax obligation owed by the Company as a result of assets of the Company or interest or other income earned on the Property, which amount shall be delivered directly to the Company by electronic funds transfer or other method of prompt payment, and the Company shall forward such payment to the relevant taxing authority; provided, **however****, that to the extent there is not sufficient cash in the Trust Account to pay such tax obligation, the Trustee shall liquidate such assets held in the Trust Account as shall be designated by the Company in writing to make such distribution so long as there is no reduction in the principal amount initially deposited in the Trust Account;** **provided**" [https://www.sec.gov/Archives/edgar/data/1863719/000119312521313591/d172566dex101.htm](https://www.sec.gov/Archives/edgar/data/1863719/000119312521313591/d172566dex101.htm) What's equally puzzling is the shares a few days ago moved to OTC. The last quoted trade price before moving to the 'Expert Markets' was $11.99. Shares a few days before that traded at $11.44. A decent size spike occurred after shares were halted on 11-29-2024 due to 'News Pending'. SPACS doing SPACKY things....
GM CEO recently said their EVs will be profitable next year. Ford meanwhile has been stopping production of EVs and made no such claims, only stating multibillion dollar losses of their EV program. GM had a rough start to the Blazer roll out, but that seems fixed as it sell three different version of it even, the Blazer, Prologue and Lyric. And the equinox seems to be a well received product. I’m starting to see some Silverado EVs around now too (though I think they are missing on that one, the WT is a bit too much vehicle, could have lower range, and needs to be cheaper).
Couple WT calls for shits and gigs
Someone smarter than me explain please How are AUR warrants worth anything right now? AYR.WT.U Trading at 76 cents The stock is 1.78 and the warrant allows you to buy a share for $2.12 That math makes no sense to me
WT...up 60% looks like this might be the ceiling as it's trending down again
Why not buy OXY warrant? Ticker OXY.WT
Good question, looks like SPYI just sucks ass relative to just SPY when both reinvest their dividends. https://testfol.io/?d=eJytjzFPw0AMhf9K5fkkwsJwc4XULSosFaoik3OC4eoLviNRFeW%2F4xIhKgYmPNl69vueZ%2BhjesZYo%2BIpg58hF9TSBCwEHsABSbiaVnXECP62snKA4bVh6SIWTgK%2B6Ac5aDG%2FdDFN4KufoemU3s3mQKjxbGaaYmTpm4klXHbvqsXBkLR0KXKyNE8zCJ4u6If6sNtMN5vtflfbJctIuWx55GD58jdWyV5Baen%2BF6lw%2B0a6Oq69qXk4s2kDaUtSvh5ajg6CYm%2B5F3cN%2F2%2B2WT7u%2F4Afl0%2BqnIie